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BACKGROUND: We evaluated the performance of primary high-risk human papillomavirus (hrHPV) testing by hybrid capture 2 (HC2)
with different thresholds for positivity, in comparison with conventional cytology.
METHODS: We used data of 25871 women (aged 30–60 years) from the intervention group of the VUSA-Screen study (VU
University Medical Center and Saltro laboratory population-based cervical screening study), who were screened by cytology and
hrHPV. Primary outcome measure was the number of cervical intraepithelial neoplasia grade 3 or higher (CIN3þ), detected within 3
years. We compared baseline cytology testing with three possible hrHPV screening strategies at different relative light unit/cutoff
(RLU/CO) thresholds.
RESULTS: Compared with baseline cytology testing, hrHPV DNA testing as a sole primary screening instrument did not yield a superior
sensitivity, as well as lower colposcopy referral rate and lower false positivity rate at any RLU/CO threshold. The hrHPV screening at
1 RLU/CO threshold with cytology triage at baseline and at 12 months revealed the highest sensitivity for CIN3þ (relative sensitivity
of 1.32), although still displaying a lower colposcopy referral rate than cytology testing (relative colposcopy rate of 0.94). Higher
thresholds (41RLU/CO) yielded lower colposcopy rates, but resulted in substantial loss in sensitivity.
CONCLUSIONS: The hrHPV testing at the commonly used threshold of 1 RLU/CO with cytology triage at baseline and at 12 months
showed a much higher sensitivity with a lower colposcopy referral rate compared with cytology testing.
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New promising methods of cervical cancer prevention have been
introduced since the recognition that infection with high-risk
human papillomavirus (hrHPV) is the necessary cause of cervical
cancer (Walboomers et al, 1999; Bosch et al, 2002; Munoz et al,
2003). The recently introduced prophylactic HPV vaccine may
have a major impact on preventing this global disease. The
prophylactic vaccines have shown to be highly effective in
preventing premalignant lesions (Harper et al, 2006; FUTURE II
Study Group, 2007; Paavonen et al, 2009; Romanowski et al, 2009).
However, it is generally agreed upon that cervical cancer screening
will need to continue even for vaccinated women (Franco et al,
2006; Goldhaber-Fiebert et al, 2008; Coupe et al, 2009).
Although cytological screening has reduced the incidence and
mortality of cervical cancer (Bray et al, 2005), it has a limited
sensitivity. The much more sensitive hrHPV test has been
suggested as an alternative primary screening instrument (Cuzick
et al, 2006; Bulkmans et al, 2007; Mayrand et al, 2007; Naucler
et al, 2007; Ronco et al, 2008, 2010), given that a clinically validated
hrHPV assay is used (Meijer et al, 2009). At present, the FDA
approved hybrid capture 2 (HC2) assay is most commonly used.
However, hrHPV testing using such a test has also shown a 4–6%
lower specificity than conventional cytology (Arbyn et al, 2006;
Cuzick et al, 2006), because many detected infections are transient
and regress without developing high-grade lesions.
In population-based screening, specificity is of utmost impor-
tance, as it basically determines the costs of the programme and
the amount of unwanted adverse effects (anxiety, repetitive and
confirmatory tests, as well as unnecessary colposcopy referrals and
treatments) in the generally healthy population. Cytological triage
of hrHPV DNA-positive women has been found to improve the
specificity of the screening test (Cuzick et al, 2006; Ronco et al,
2006b; Naucler et al, 2009). Another, easier and potentially cost
saving option is to adapt the threshold, that is, increase the relative
light unit/cutoff (RLU/CO) threshold, of the HC2 test. This would
particularly be useful if it obviates the need for repeat testing.
Several studies have examined baseline hrHPV testing strategies
with triage of hrHPV-positive women at higher thresholds than the
one conventionally used (i.e., RLU/CO of X1) (Clavel et al, 2001;
Hesselink et al, 2006; Kotaniemi-Talonen et al, 2008; Ronco
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set al, 2008; Sargent et al, 2010). This did not result in a strategy
that ensured higher sensitivity as well as higher specificity in terms
of lower colposcopy referral rates compared with cytological
screening.
The aim of this study was to investigate the effect of hrHPV HC2
testing with higher thresholds on the sensitivity and specificity in
terms of colposcopy referral rate and false positivity rate,
considering a number of different hrHPV screening strategies.
We searched for strategies that improved the specificity of hrHPV
screening by increasing the RLU/CO threshold, while maintaining
a higher sensitivity than baseline cytological testing. We used data
from the intervention group of the VUSA-Screen study (VU
University Medical Center and Saltro laboratory population-based
cervical screening study), a study performed within the routine
cervical programme of the Netherlands. Women participating in
this cohort received combined hrHPV testing and cytology. The
primary end points were cervical intraepithelial neoplasia grade 3
or higher (CIN3þ), detected within 3 years.
MATERIALS AND METHODS
Study design VUSA-screen
The VUSA-Screen is a population-based study designed to evaluate
the effectiveness of combined cervical cytology screening with
hrHPV testing by HC2 hybridisation assay (Qiagen, Gaithersburg,
MD, USA). The study was carried out in the Utrecht province of
the Netherlands in the setting of the regular screening programme
that invites women, aged between 30 and 60 years of age, to be
screened every 5 years. The design of the study has also been
described elsewhere (Rijkaart et al, 2009). Between October 2003
and August 2005, women invited for the regular cervical screening
programme were asked to participate in the VUSA-Screen study.
Women were excluded from the analysis if they had a history of
cervical intraepithelial neoplasia grade 2 or higher (CIN2þ)o r
abnormal cytology in the preceding 2 years. Women who agreed to
receive cytology and hrHPV testing gave written informed consent.
Conventional cytological smears were taken with a cytobrush
(Rovers, Oss, The Netherlands). After preparation of a conven-
tional smear on a glass slide, the brush was placed in a vial
containing 1ml UCM (Universal Collection Medium, Digine Corp.,
Gaithersburg, MD, USA) for hrHPV testing. Cervical cytology
results were reported, blinded to the hrHPV testing results,
according to the CISOE-A classification, which is routinely used in
The Netherlands and can be converted into the 2001 Bethesda
system (Bulk et al, 2004). Cytological results were grouped as
normal, BMD (borderline or mild dyskaryosis) and 4BMD
(moderate dyskaryosis or worse). In the 2001 Bethesda system,
BMD corresponds to atypical squamous cells of undetermined
significance; atypical squamous cells cannot rule out high-grade
squamous intraepithelial lesions; or low-grade squamous intrae-
pithelial lesions and 4BMD corresponds to high-grade squamous
intraepithelial lesions.
Women with BMD or worse were informed about the hrHPV
test result. The hrHPV-positive women with BMD and all women
with 4BMD were directly referred for colposcopy (Figure 1).
Women with BMD at baseline and a negative hrHPV test were
offered cytology testing at 6 and 18 months and referred if cytology
was abnormal (threshold BMD) at one of these occasions.
In the women with normal cytology at baseline, a sub-study was
carried out. In this sub-study, all (n¼1021) hrHPV-positive
women as well as a subset of hrHPV-negative cytologically
normal women (n¼3063) were included. To select the hrHPV-
negative women, each hrHPV-positive woman was matched to
three randomly chosen hrHPV-negative women of the same age.
Women with normal cytology were not informed about the hrHPV
test result. The hrHPV-positive women with normal cytology were
offered cytology and a blinded hrHPV test at 12 months, and
combined hrHPV testing and cytology at 24 months. A woman was
referred at 12 months if cytology was abnormal and at 24 months
if the hrHPV test was positive and/or cytology was abnormal.
The hrHPV-negative, cytologically normal women in the sub-study
were invited for combined testing at 24 months, and referred if
cytology was abnormal and/or the hrHPV test was positive. If a
woman with normal cytology and a negative hrHPV test was not
n=25 871
cytology and
hrHPV
Inadequate
0.8%
n=213
hrHPV–
95.9%
n=24 175
Next screening
round
n=21 112
Repeat smear &
hrHPV n=3 063
at 24 months
Referral colpo
if cyto BMD or
hrHPV+
Referral colpo at
12 m if cyto BMD
24 m if cyto BMD
or hrHPV+
Referral colpo
if cyto BMD
Repeat smear and
hrHPV n=1 021 at 
12 and 24 months
Repeat smear 
at 6 and 18 
months
Referral
colposcopy
Referral
colposcopy
hrHPV+
4.1%
n=1 021
hrHPV–
50.4%
n=170
hrHPV+
49.6%
n=167
BMD
1.3%
n=337
>BMD
0.5%
n=125
Independent of
hrHPV test
Normal
97.4%
n=25 196
Figure 1 Flowchart of the study design. BMD, borderline or mild dyskaryosis; colpo, colposcopy; cyto, cytology; hrHPV, high-risk human papillomavirus;
m, months.
HC2 RLU/CO threshold
DC Rijkaart et al
940
British Journal of Cancer (2010) 103(7), 939–946 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sinvited for repeat testing after 24 months, cytological and/or
histological follow-up results was not included.
The VUSA-Screen study was approved by the Ministry of Public
Health (2002/02-WBO; ISBN-10: 90-5549-452-6) and registered in
the trial register (NTR215, ISRCTN64621295).
Colposcopy
Of the women who were referred to a gynaecologist for colposcopy,
colposcopy-directed biopsies were taken from suspicious areas of
the cervix, according to standard procedures in the Netherlands
(Hopman et al, 2000). Biopsy results were reported as normal,
cervical intraepithelial neoplasia grade 1, 2, 3, or as invasive
cancer, according to the international criteria (Anderson, 1995;
Wright, 2009). Cytology and histology results were retrieved from
the nationwide network and registry of histopathology and
cytopathology (PALGA; Bunnik, The Netherlands).
hrHPV testing
The hrHPV testing was performed by the HC2 high-risk HPV DNA
test in an automated format on a rapid capture system according
to the manufacturer’s instructions (Qiagen). This test uses a
cocktail probe to detect 13 high-risk HPV types: 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59 and 68. Positive controls containing
1pgml
 1 of cloned HPV-16 DNA and negative controls (provided
by the manufacturer) were included in each assay (Qiagen).
The results of the HC2 assay were expressed as RLU/CO ratio,
representing the ratio between the emission from a sample to the
average emission of three positive controls. Initially, the threshold
of 1 RLU/CO, as proposed by the manufacturer, was used to
classify a specimen as positive or negative.
Statistical analysis
The primary outcome measure of the study was histologically
confirmed CIN3þ, detected cumulatively within 3 years after
baseline. A secondary outcome was cumulatively detected CIN2þ.
In the calculations of the number of CIN3þ and CIN2þ lesions,
cases of cervical adenocarcinoma and cervical adenocarcinoma
in situ were also included.
The absolute specificity of hrHPV testing with RLU/CO thresh-
olds between 1 and 100 and the absolute specificity of cytology
were computed as follows. Specificities were adjusted for non-
attendance at repeat testing by applying Bayes’s rule, which means
that the specificities were computed from the positive and negative
predictive values for CIN3þ (and CIN2þ), as well as the baseline
prevalences of HC2 and cytology test outcome strata (Begg
and Greenes, 1983; Kulasingam et al, 2002). For this purpose, the
baseline test outcomes were grouped into seven strata: (1) 4BMD
and hrHPVþ, (2) 4BDM and hrHPV , (3) BMD and hrHPVþ,
(4) BMD and hrHPV , (5) normal and hrHPVþ, (6) normal
and hrHPV , and age p35 years, and (7) normal and hrHPV ,
and age 435 years. We defined two separate age strata for hrHPV-
negative women with normal cytology at baseline because
hrHPV-negative normal women were age-matched to hrHPV-
positive normal women, and women p35 years were therefore
overrepresented in follow-up. The positive and negative predictive
values were computed only on the basis of women with at least one
repeat test. For hrHPV-positive, cytologically normal women, the
12-month screening tests were used as repeat tests. The 24-month
screening tests were used if the 12-month tests were missing. For
BMD hrHPV-negative women, the 6-month results were used as
repeat test results and the 18-month results were used if the
6-month results were missing. The specificities presented were
therefore adjusted for women without repeat testing, but were not
adjusted for differences in intensity of follow-up testing among
women with at least one repeat test.
Furthermore, we compared baseline cytology (threshold BMD)
with three possible hrHPV screening strategies at RLU/CO
thresholds between 1 and 100. The following hrHPV screening
strategies were used: (1) baseline hrHPV testing only; (2) cytology
triage of hrHPV-positive women at baseline and one repeat
cytological test for cytologically normal women; and (3) cytology
triage of hrHPV-positive women at baseline and one repeat
combined cytology and hrHPV HC2 test (with RLU/CO values as
used at baseline) for cytologically normal women. For each
comparison, we computed the relative sensitivity for CIN3þ (and
CIN2þ), relative false positivity rate and relative colposcopy
referral rate. Analogous to the calculation of the specificity, the
relative rates were calculated by combining positive and negative
predictive values (here for CIN3þ, CIN2þ and colposcopy
referral) and baseline test outcomes. Because double-negative
women cancel out when calculating relative rates (Pepe and
Alonzo, 2001), we only needed to define five baseline strata:
(1) 4BMD and hrHPVþ, (2) 4BDM and hrHPV , (3) BMD and
hrHPVþ, (4) BMD and hrHPV  and (5) normal and hrHPVþ.
The 95% confidence intervals (CIs) were calculated for absolute
specificity using the Wilson Score method (Brown et al, 2001),
in which the sample size was set equal to the number of cases
observed in the cohort study.
Analyses were done with SPSS version 15.0 (LEAD Technologies
Inc, Haddonfield, NJ, USA), and Excel (Microsoft Corporation,
Redmond, WA, USA).
RESULTS
Study subjects
Of the 25871 women from the intervention group of VUSA-Screen
study, 25658 (99.2%) had an adequate baseline Pap smear. Among
women with adequate Pap smears, 25196 had normal cytology of
whom 1021 (4.1%) tested hrHPV-positive, 337 women had a BMD
result of whom 167 (49.6%) tested hrHPV-positive and 125 women
had a 4BMD result of whom 115 (92.0%) tested hrHPV-positive.
The median age of participating women was 44.0 years (range,
29–61 years). The hrHPV results of positive RLU/CO (i.e., RLU/
CO X1) showed a mean of 224.5 (range, 1.0–2565.7).
The number of test positives and negatives, CIN3þ and CIN2þ
detected, stratified for cytology and HC2 thresholds are presented
in Table 1.
Table 2 presents the specificity for detected CIN3þ and CIN2þ
lesions for baseline cytology testing (threshold BMD) and for a
strategy of primary HC2 testing without follow-up testing at
different RLU/CO thresholds. Compared with baseline cytology
testing, hrHPV testing at the standard threshold of 1 RLU/CO had
a lower specificity for CIN3þ (95.5 vs 98.7%) and CIN2þ (95.9 vs
98.9%). The specificity for CIN3þ and CIN2þ increased with
increasing RLU/CO thresholds. Only at a RLU/CO threshold of 100,
hrHPV testing reached the same specificity for CIN2þ (i.e.,
98.9%) and CIN3þ (i.e., 98.7%) as cytology.
The relative colposcopy referral rate, relative sensitivity and
relative false positivity rate of primary HC2 testing at different
RLU/CO thresholds vs baseline cytology testing are presented in
Table 3. Compared with cytology, hrHPV testing at a threshold of 1
RLU/CO would result in a 2.8-fold higher number of colposcopy
referral rates. With increasing HC2 threshold, the relative
colposopy referral rates decreased, resulting in a relative rate of
1.9 at 10 RLU/CO and 0.94 at 100 RLU/CO.
At the standard test positivity threshold for HC2 (i.e., 1 RLU/
CO), the relative sensitivity of hrHPV was superior to that of
cytology, both for CIN3þ (relative sensitivity of 1.36) and CIN2þ
(relative sensitivity of 1.50). With increasing HC2 threshold values,
the relative sensitivity for CIN3þ decreased, resulting in a relative
sensitivity of 1.22 at 10 RLU/CO and 0.80 at 100 RLU/CO. Results
were comparable using CIN2þ as outcome measure.
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sThere was no HC2 threshold that resulted in an improved false
positivity rate and concomitant colposcopy referral rate, without
compromising its sensitivity. In fact, the HC2 threshold (i.e., 100
RLU/CO) at which a lower colposcopy referral rate was reached
compared with cytology, also revealed lower sensitivities for
CIN3þ and CIN2þ (Table 3). As no strategy of sole hrHPV
testing at baseline improved on baseline cytology testing, some
form of triage or follow-up testing is required.
Table 4 shows the impact of raising the HC2 threshold in the
context of two triage and follow-up strategies for HC2-positive
women compared with baseline cytology testing. For the strategy
with cytology triage at baseline and at 12 months, HC2 screening
Table 2 Comparison of specificity between baseline hrHPV test with different RLU/CO thresholds and baseline cytology testing for CIN3+ and CIN2+,
adjusted for non-attendance at repeat testing
End point CIN3+ End point CIN2+
Test Specificity (%) 95% CI Specificity (%) 95% CI
Baseline cytology (threshold BMD) 98.7 98.5–98.8 98.9 98.8–99.0
Baseline HC2 positivity threshold, RLU/CO
1 95.5 95.3–95.8 95.9 95.7–96.2
2 96.2 95.9–96.4 96.5 96.3–96.8
5 96.7 96.5–96.9 97.1 96.8–97.3
7 96.9 96.7–97.1 97.2 97.0–97.4
10 97.2 96.9–97.4 97.5 97.3–97.7
30 98.0 97.8–98.1 98.3 98.1–98.4
50 98.2 98.0–98.4 98.5 98.3–98.6
100 98.7 98.5–98.8 98.9 98.7–99.0
Abbreviations: BMD¼borderline or mild dyskaryosis; CI¼confidence interval; CIN¼cervical intraepithelial neoplasia (grade 2 or 3 or higher); HC2¼hybrid capture 2;
hrHPV¼high-risk human papillomavirus; RLU/CO¼relative light unit/cutoff.
Table 1 Number of test positives and negatives, CIN3+ and CIN2+ detected, stratified for cytology and HC2 thresholds
Histology
End point CIN3+ End point CIN2+
Test positive Test negative Detected Missed Detected Missed
Test n (% of total n¼25658) n nnnn
Baseline cytology (threshold BMD) 462 (1.80) 1021 124 27 181 57
HC2 cutoff
1 1303 (5.08) 180 146 5 227 11
2 1147 (4.47) 336 144 7 224 14
5 1006 (3.92) 477 141 10 216 22
7 954 (3.72) 529 137 14 212 26
10 877 (3.42) 606 131 20 203 35
30 654 (2.55) 829 118 33 184 54
50 572 (2.23) 911 104 47 162 76
100 433 (1.69) 1050 89 62 133 105
Abbreviations: BMD¼borderline or mild dyskaryosis; CIN¼cervical intraepithelial neoplasia (grade 2 or 3 or higher); HC2¼hybrid capture 2.
Table 3 Relative colposcopy referral rates, relative sensitivity, relative false positivity rate of HC2 RLU/CO thresholds at baseline alone vs baseline
cytology testing, adjusted for non-attendance at repeat testing
End point CIN3+ End point CIN2+
Test
Relative colposcopy
referral rate
Relative
sensitivity
Relative false
positivity rate
Relative
sensitivity
Relative false
positivity rate
Baseline cytology (threshold BMD) Reference Reference Reference Reference Reference
Baseline HC2 positivity threshold, RLU/CO
1 2.82 1.36 3.35 1.50 3.67
2 2.48 1.34 2.89 1.48 3.12
5 2.18 1.31 2.49 1.42 2.65
7 2.06 1.28 2.34 1.40 2.48
10 1.90 1.22 2.14 1.34 2.25
30 1.42 1.08 1.53 1.20 1.55
50 1.24 0.95 1.34 1.05 1.35
100 0.94 0.80 0.99 0.82 1.01
Abbreviations: BMD¼borderline or mild dyskaryosis; CIN¼cervical intraepithelial neoplasia (grade 2 or 3 or higher); HC2¼hybrid capture 2; RLU/CO¼relative light unit/cutoff.
HC2 RLU/CO threshold
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sat RLU/CO thresholds between 1 and 30 resulted in higher
sensitivities for both CIN2þ and CIN3þ, compared with baseline
cytology testing. This strategy showed lower colposcopy referral rates
and false positivity rates at all analysed RLU/CO thresholds (1–100).
For the strategy with cytology triage at baseline and combined
cytology and HC2 testing (with the same threshold as used at
baseline) at 12 months, only at threshold 30, a lower false positivity
and colposcopy rate in combination with higher sensitivities for
CIN3þ and CIN2þ than baseline cytology testing was found.
However, at RLU/CO 30, the gain in sensitivity compared with
cytology was only marginal.
The relative sensitivity vs relative false positivity rate of the
three investigated screening strategies, compared with baseline
cytology testing, is graphically shown in Figure 2. Baseline cytology
testing is presented in the origin (relative sensitivity¼1, relative
specificity¼1). Quadrant II represents combinations of sensitivity
and false positivity rates that are superior to baseline cytology
testing. The strategy with baseline HC2 testing alone was inferior
to baseline cytology testing for all RLU/CO thresholds. The
strategy with cytology triage of HC2-positive women and cytology
testing at 12 months showed the best combination of relative
sensitivity and false positivity rates for RLU/CO between 1 and 30.
The RLU/CO data points for this strategy form a steep curve. This
indicates that at increasing RLU/CO thresholds, the reduction in
false positivity rate in this strategy is relatively small, whereas the
decrease in sensitivity is substantial. Thus, low RLU/CO values are
required to maintain high sensitivity.
DISCUSSION
In this study, we evaluated three possible cervical screening
strategies that are based on hrHPV testing with different HC2
thresholds and compared them with baseline cytology testing
(threshold BMD). We aimed to improve the specificity of hrHPV
screening by increasing the RLU/CO threshold, while maintaining
a higher sensitivity than baseline cytological testing. The results
are based on data from the VUSA-Screen study, a population-
based cohort study carried out in the Utrecht province of the
Netherlands. We found that compared with baseline cytology
testing, there was no HC2 RLU/CO threshold for which a screening
strategy of hrHPV testing as a sole primary screening instrument
resulted in both superior sensitivity as well as similar (or lower)
colposcopy rate and equal (or higher) specificity. As baseline
hrHPV testing cannot improve baseline cytology testing, even at
increased RLU/CO thresholds, we conclude that some form of
triage and follow-up is required in hrHPV screening.
Given that follow-up testing is required in hrHPV-positive
women, we searched for a strategy that did not increase
colposcopy referral rate compared with cytological testing. A
screening strategy that was clearly superior to baseline cytological
testing was primary hrHPV screening, with RLU/CO thresholds
between 1 and 30 and cytology triage at baseline and repeated
cytology testing at 12 months. This strategy was not only more
sensitive than baseline cytology testing but also resulted in lower
false positivity rates and in fewer colposcopy referrals. Using HC2
RLU/CO thresholds between 1 and 5 results in higher sensitivity
(relative sensitivity between 1.32 and 1.25, respectively) and a
reduced colposcopy referral rate (between 6 and 16%, respectively)
compared with baseline cytology testing. The current threshold of
1 RLU/CO makes optimal use of the superior sensitivity of
the hrHPV test for CIN3þ/CIN2þ, without actually increasing
the colposcopy referral rate compared with baseline cytology. The
colposcopy referral rate of this strategy is therefore substantially
lower than a screening scenario with baseline hrHPV testing only.
In addition, a screening strategy with a high sensitivity may allow
for extension of the screening interval, which in turn reduces
colposcopy referral rates (Berkhof et al, 2010).
An important issue in the debate about implementation
of hrHPV testing has been the increased adverse effects in terms
of unnecessary referrals for colposcopy among women with a
positive hrHPV test. The issue of overdiagnosis and overtreatment
Table 4 Relative colposcopy referral rates, relative sensitivity, relative false positivity rate of HC2 positivity threshold with baseline triage and repeat testing
strategy vs baseline cytology testing, adjusted for non-attendance at repeat testing
End point CIN3+ End point CIN2+
Test
Relative
colposcopy
referral rate
Relative
sensitivity
Relative
false positivity
rate
Relative
sensitivity
Relative
false positivity
rate
Baseline cytology
(threshold BMD)
Reference Reference Reference Reference Reference
Baseline HC2 positivity
threshold, RLU/CO
Baseline
triage test
Repeat test
at 12 months
1 Cytology Cytology 0.94 1.32 0.80 1.36 0.67
2 Cytology Cytology 0.89 1.29 0.74 1.34 0.60
5 Cytology Cytology 0.84 1.25 0.69 1.31 0.60
7 Cytology Cytology 0.82 1.22 0.68 1.29 0.52
10 Cytology Cytology 0.79 1.17 0.65 1.23 0.50
30 Cytology Cytology 0.65 1.02 0.52 1.09 0.38
50 Cytology Cytology 0.57 0.90 0.45 0.96 0.33
100 Cytology Cytology 0.46 0.75 0.36 0.74 0.28
1 Cytology Cytology and HC2
a 1.88 1.36 2.07 1.50 2.12
2 Cytology Cytology and HC2
a 1.68 1.34 1.81 1.47 1.82
5 Cytology Cytology and HC2
a 1.45 1.30 1.51 1.40 1.48
7 Cytology Cytology and HC2
a 1.37 1.27 1.41 1.37 1.37
10 Cytology Cytology and HC2
a 1.30 1.21 1.33 1.29 1.30
30 Cytology Cytology and HC2
a 0.96 1.05 0.92 1.14 0.84
50 Cytology Cytology and HC2
a 0.81 0.93 0.76 1.01 0.68
100 Cytology Cytology and HC2
a 0.59 0.76 0.52 0.78 0.46
Abbreviations: BMD¼borderline or mild dyskaryosis; CIN¼cervical intraepithelial neoplasia (grade 2 or 3 or higher); HC2¼hybrid capture 2; RLU/CO¼relative light
unit/cutoff.
aHC2 RLU/CO threshold as at baseline.
HC2 RLU/CO threshold
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sis of particular importance for women of reproductive age, because
it has been shown that the rate of serious obstetrical complications,
such as preterm deliveries, low birth weight and premature rupture
of the membranes, is increased after excisional treatments for
precancerous lesions (Kyrgiou et al, 2006). Therefore, there is a
need to identify strategies that minimise the need for colposcopy
referrals with hrHPV testing, while maintaining its advantage in
terms of sensitivity. A number of studies have evaluated the
optimisation of cervical screening by studying the different hrHPV
HC2 cutoff levels for test positivity (Kuhn et al, 2000; Schiffman
et al, 2000; Clavel et al, 2001; Kulmala et al, 2004; Ronco et al,
2006a,b; Kotaniemi-Talonen et al, 2008; Sargent et al, 2010).
Kotaniemi-Talonen et al concluded that when used as a sole
screening test, the hrHPV test cutoff level can be increased to 10
RLU/CO. The specificity of hrHPV screening, however, remained
lower than that with conventional cytology testing even at the
threshold of 10 RLU/CO. This is in line with our findings for the
strategy of baseline HC2 testing only. It should be noted that the
hrHPV test may compare to be more favourable with cytology in
other countries. In the Netherlands and Finland, the specificity of
cytology is quite high. This is also the case for other European
screening programmes (Cuzick et al, 2006), but worldwide the
specificity of cytology is highly variable (Nanda et al, 2000). Ronco
et al (2006a,b) proposed only a slight increase of the threshold up
to 2.00 RLU/CO when HC2 is used for population-based screening.
The same threshold has been proposed by Sargent et al (2010). A
minimal increase in threshold reflects a preference for a sensitive
screening strategy. We found that, in an hrHPV DNA screening
strategy with cytology triage and cytology testing at one follow-up
visit, an increased sensitivity as well as decreased colposcopy
referral rate is possible with RLU/CO thresholds up to 30. Given
our observation that hrHPV testing cannot be used as a sole
screening instrument and that triage and repeated testing is
necessary anyhow, we also prefer a low threshold of 1 to maintain
the highest sensitivity.
There are some limitations in our study. In this study, women
received cytology and hrHPV testing, and based on both results,
women were referred for colposcopy. Therefore, we were not able to
compare different RLU/CO thresholds outcomes with current
cytology screening programme but only with baseline cytology
testing. Furthermore, we adjusted for non-attendance at repeat
testing, but the results were not adjusted for differences in intensity
of follow-up testing. In addition, actual colposcopies were not
reported. Another limitation of our study may be the use of a
subjective test, such as cytology, as a triage test for hrHPV-positive
women. Awareness of the negative or positive hrHPV test result may
affect the criteria for defining cellular abnormalities. However, in this
study, the cytotechnicians were not informed about the hrHPV test
result. Nevertheless, even in case cytotechnicians were aware of the
hrHPV test results, as in a Finnish trial (Leinonen et al, 2009), the
hrHPV test information only had a small effect on cytology
assessment, and therefore on the CIN3þ detection rate and the
number of colposcopies. In this context, it may be expected that in
the near future molecular biomarkers may be used as objective triage
tests of hrHPV-positive women. Suitable candidate novel biomarkers
such as HPV mRNA (Molden et al, 2005), p16 ink4a (Carozzi et al,
2008), methylation markers (Overmeer et al, 2008, 2009) or
genotyping might further enhance the efficacy of screening with
hrHPV DNA (Cuschieri et al, 2004). Presently, we are investigating
the possible value of such alternative triage tests in hrHPV-positive
women and preliminary results show that better results can be
obtained than with cytology (Heideman et al, 2010).
Our finding that hrHPV testing alone at the predefined assay
threshold of 1 RLU/CO had a somewhat lower specificity than
cytology for CIN2þ and CIN3þ is consistent with results from
other randomised and nonrandomised studies using HC2 testing
(Kotaniemi-Talonen et al, 2005; Arbyn et al, 2006; Cuzick et al,
2006, 2008; Ronco et al, 2006a,b; Mayrand et al, 2007; Kitchener
et al, 2009; Leinonen et al, 2009) or another clinically validated
hrHPV test (Bulk et al, 2007; Naucler et al, 2007). However,
compared with these studies, our observed specificity of the
hrHPV test was relatively high (i.e., 95.9% (95% CI 95.7–96.2) for
CIN2þ and 95.5% (95% CI 95.3–95.8) for CIN3þ). At least in
part, this difference in specificity estimates may be explained by
differences in the design of hrHPV screening studies and study
populations. Our study included hrHPV testing combined with
cytology. In addition, it was conducted within the setting of an
organised cervical screening programme with high invitational
coverage and low incidence of cervical cancer.
A strong point of this study is the longitudinal design and the
older age range of study participants (30–60 years), which is the
age for which hrHPV testing is most widely advocated (Wright Jr
et al, 2004; Naucler et al, 2007; Ronco et al, 2009). The study was
population-based and part of a routine organised screening
activity in a low-risk population, indicating that the results could
be implemented in routine practice.
To conclude, no RLU/CO threshold was found for which HC2
testing at baseline resulted in a similar or lower colposcopy referral
rate than baseline cytology, while maintaining a higher sensitivity.
Superior combinations of sensitivity and colposcopy rate are
possible for HC2 testing with cytology triage at baseline and
repeated cytology testing after 1 year. As increasing the RLU/CO
threshold only marginally decreases colposcopy referral rate while
substantially reducing sensitivity, we suggest maintaining the
currently used RLU/CO threshold of 1. This results in more than
30% higher sensitivities for CIN3þ than cytology testing at a 20%
lower false positivity rate and 6% lower colposcopy referral rate.
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Figure 2 Relative sensitivity vs relative false positivity rate for three
strategies for hybrid capture 2 (HC2)-positive women at different relative
light unit/cutoff (RLU/CO) thresholds compared with baseline cytology
(cyto) testing, for detection of cervical intraepithelial neoplasia grade 3 or
higher (CIN3þ). Relative sensitivity for detection of CIN3þ is plotted on
the y-axis, against the relative false positivity rate on the x-axis. The used
HC2 RLU/CO thresholds are indicated at the respective positions above
each plot. I: quadrant with relative sensitivity and relative false positivity rate
greater than cytology; II: panel with relative sensitivity greater than and
relative false positivity rate lower than cytology; III: panel with relative
sensitivity lower than and relative false positivity rate lower than cytology;
IV: panel with relative sensitivity and relative false positivity rate lower than
cytology. BMD, borderline or mild dyskaryosis.
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